Faculty

Felipe Batalini, M.D.

Clinical Studies

A Phase 1, First-in-human, Dose Escalation And Expansion, Multicenter Study Of XMT-1660 In Participants With Solid Tumors Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.
The purpose of this study is to test the safety and side effects of a drug called XMT-1660.
Phase 1/2 Study Of PARG Inhibitor ETX-19477 In Patients With Advanced Solid Malignancies Jacksonville, Fla., Rochester, Minn.
The purpose of this study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.
This is a multicenter, Phase 1b/2 trial. The purpose of phase 1b part of the trial aims to determine the recommended phase II dose (RP2D) of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, and ribociclib. The Phase 2 part of the trial will evaluate the effectiveness and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.

Phase 1/2 Study Of PARG Inhibitor ETX-19477 In Patients With Advanced Solid Malignancies Scottsdale/Phoenix, Ariz.
The purpose of this study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.
Phase 1b/2 Study Of ATR InhibiTor RP-3500 And PARP Inhibitor Combinations In Patients With Molecularly Selected Cancers (ATTACC) Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn. The primary purpose of this study is to assess the safety and tolerability of Niraparib or Olaparib in combination with RP-3500, in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-3500 in combination with Niraparib or Olaparib, examine pharmacokinetics (PK) and assess anti-tumor activity.